cui image

Taixing Cui, MD, Ph.D.

Assistant Professor of Cell Biology & Anatomy
University of South Carolina School of Medicine

Contact:
Office:  803-216-3804
Lab:     803-216-3833
Fax:     803-216-3846
Email: taixing.cui@uscmed.sc.edu

Pubmed

1989 The 4th Military Medical University – M.D. – P.R. China
2001 Ehime University School of Medicine – Ph.D. – Molecular Medicine  

Research Focus:

The majority of cardiovascular disease results from complications of vascular disorders, e.g., atherosclerosis that becomes worse under the circumstance with obesity and diabetes. Dr. Cui has a research interest in vascular biology with special reference to the vasculopathy associated with obesity and diabetes. Dr. Cui’s laboratory takes a multi-disciplinary approach to address the molecular and cellular mechanism that links obesity, diabetes and vascular disease, with a specific focus on the role of ubiquitin-proteasome system in the maintenance of vascular homeostasis. 

There are four areas of technical strengths in Dr. Cui’s laboratory: 1) molecular biology including most of the routine DNA, RNA and protein techniques; 2) cellular biology including primary culture of vascular smooth muscle cells, endothelial cells, macrophages and adipocytes, dissection of signal transduction pathways involved in cellular metabolism, migration and proliferation as well as inflammatory responses; 3) development and characterization of animal models of vascular disease through transgenic approaches; 4) vascular physiology analyses in cell, organ and whole animal levels. 

Two major projects currently underway include:

  1. Defining mechanism that regulates Keap1-mediated Nrf2 ubiquitination, degradation, anti-oxidative gene expression in vasculature.
  2. Determining mechanism that controls the deubiquitinating enzymes such as UCH-L1- or CYLD-mediated suppression of inflammatory responses in vasculature.

Recent Publications

  • Bai Y, Cui W, Xin Y, Miao X, Barati MT, Zhang C, Chen Q, Tan Y, Cui T, Zheng Y, Cai L (2013) Prevention by sulforaphane of diabetic cardiomyopathy is associated with up-regulation of Nrf2 expression and transcription activation. J Mol Cell Cardiol 57:82-95.
  • Wang Y, Sun W, Du B, Miao X, Bai Y, Xin Y, Tan Y, Cui W, Liu B, Cui T, Epstein PN, Fu Y, Cai L (2013) Therapeutic effect of MG-132 on diabetic cardiomyopathy is associated with its suppression of proteasomal activities: roles of Nrf2 and NF-κB. Am J Physiol Heart Circ Physiol 304(4):H567-578.
  • Xing Y, Niu T, Wang W, Li J, Li S, Janicki JS, Ruiz S, Meyer CJ, Wang XL, Tang D, Zhao Y, Cui T (2012) Triterpenoid dihydro-CDDO-trifluoroethyl amide protects against maladaptive cardiac remodeling and dysfunction in mice: a critical role of Nrf2. PLoS One 7:e44899.
  • Tan Y, Ichikawa T, Li J, Si Q, Yang H, Chen X, Goldblatt CS, Meyer CJ, Li X, Cai L, Cui T (2011) Diabetic downregulation of Nrf2 activity via ERK contributes to oxidative stress-induced insulin resistance in cardiac cells in vitro and in vivo. Diabetes 60:625-633.
  • Li J, Zhang C, Xing Y, Janicki JS, Yamamoto M, Wang XL, Tang DQ, Cui T (2011) Up-regulation of p27(kip1) contributes to Nrf2-mediated protection against angiotensin II-induced cardiac hypertrophy. Cardiovasc Res 90:315-324.
Click for older publications